New York, February 13th, 2025 – Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel therapeutics that target molecular mechanisms of regulated cell death for immune mediated diseases, today announced the dosing of their first patient in the Phase Ib clinical trial of AC-101. AC-101 is a novel RIPK2 inhibitor being developed for the treatment of moderate-to-severe Ulcerative Colitis (UC).
Company to conduct a Phase II multi-regional clinical trial (MRCT) for the treatment of Ulcerative Colitis (UC)
Suzhou China, November 26, 2024 - Accro Bioscience (Suzhou) Limited (Accropeutics), a clinical-stage biotech company with a focus on molecular mechanisms of regulated cell death and related pathogenesis in human diseases, today announced that the highly selective TYK2/JAK1 inhibitor AC-201 has received approval from the National Medical Products Administration (NMPA) for a phase II clinical trial to treat non-infectious uveitis.
Suzhou, China, May 6th, 2024——Accro Bioscience (Suzhou) Limited (Accropeutics) announced today that the first psoriasis patient has been dosed in the phase 2 clinical trial of the TYK2/JAK1 inhibitor AC-201 in China. This study is a multicenter, randomized, double-blind, parallel group, placebo-controlled phase II clinical trial to evaluate the efficacy, safety, and pharmacokinetic characteristics of AC-201 in subjects with moderate to severe plaque psoriasis.
Suzhou China, April 26, 2024 - Accro Bioscience (Suzhou) Limited (Accropeutics), a clinical-stage biotech company with a focus on molecular mechanisms of regulated cell death and related pathogenesis in human diseases, today announces positive results at the completion of the Phase I study of its drug candidate AC-101 in healthy human subjects. The Phase I trial was a single center, randomized, double-blind, placebo-controlled, single and multiple ascending dose study following oral administration in healthy human subjects, to evaluate the safety, tolerability, pharmacokinetics and the effects of food of AC-101.
Suzhou China, December 25, 2023 —— Accro Bioscience (Suzhou) Limited (Accropeutics) announced that its RIPK1 inhibitor AC-003 capsules for the treatment of acute Graft-versus-Host Disease (aGvHD) has been granted Orphan Drug Designation (ODD) by the US Food and Drug Administration (FDA).
